Trends in Pharma – Report Bundle (4 Reports)
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Trends in Pharma Industry Overview
‘The pharmaceutical sector is witnessing a massive revamp. It has been conventionally slow in the adoption of technology and is now undergoing rapid changes due to the development of several technologies as well as innovations. From modern cancer research facilities to gene treatment centers, the novel association between the human mind and technology has become a self-evolving matter. Post-COVID, equipped with cutting-edge technology, the prominent pharma industry tends to invest increasingly in inter-organizational collaborations to boost a favorable environment for innovation across it. ’
As a part of this bundle, you will gain access to in-depth insights available in the following reports:
- The State of the Biopharmaceutical Industry
- Thematic Research: Neuroimmunology Drug Development
- Thematic Research: Microbiome-Targeting Therapeutics in Immunology
- Thematic Research: Gene Therapy in Oncology
To get a snapshot of the trends in pharma bundle, download a free report sample
Report 1: The State of the Biopharmaceutical Industry
COVID-19 has been a wake-up call for the pharmaceutical industry to innovate, rethink its operations, and adopt new ways of working. To harness relationships with customers, regulators, and investors, it is understood that digitalization is going to be an inseparable part of the industry’s transformation roadmaps. The healthcare industry made quick decisions and fast investments to ensure business continuity, dispelling the stereotype of being risk-averse. AI, followed by big data, will continue to trend as an integral part of the future of pharmaceutical research and healthcare service delivery. With the increasing volume and complexity of data being generated by the sector, the need to analyze information will continue to pose challenges that can be best addressed by AI. As pressures to manage sustainability risks are intensifying on a global scale, the pharmaceutical industry will need to act on this trend as well. As a part of post-COVID-19 recovery agendas, many businesses have already started incorporating greener processes in R&D, supply chain, waste, and resource management to address ESG issues.
For more insights on the state of the biopharmaceutical industry, download a free report sample
Report 2: Thematic Research: Neuroimmunology Drug Development
Key industry trends in neuroimmunology drug development include the application of similar mechanisms of action (MOA) across numerous indications as well as the development of mAbs targeting pathogenic neural proteins in Alzheimer’s disease (AD) and Parkinson’s disease (PD), among others. Across the 8MM, the top 20 neuroimmunology products, by sales, are forecast to increase from $20.1 billion in 2020. Ocrevus is expected to be the highest-earning product. In the neuroimmunology space, Roche and its subsidiaries, Chugai and Genentech, market Ocrevus for MS and Enspryng for NMOSD. The company also has nine pipeline products in clinical development.
For more insights on neuroimmunology drug development, download a free report sample
Report 3: Thematic Research: Microbiome-Targeting Therapeutics in Immunology
Small and mid-sized biotech companies currently dominate the pipeline for microbiome-targeting therapeutics. Players from large pharma companies, such as Takeda and J&J have made it a priority to partner with smaller biotech companies and academy labs to further the development of microbiome-targeting therapeutics in immunology. No microbiome targeting therapy has received marketing approval yet. Although regulatory agencies are adapting preexisting guidance for other types of drugs to microbiome-targeting therapies, specific guidance for this new class of drugs will likely be established over the next decade. Developers must anticipate regulatory agency concerns as best they can, but without specified guidance, there may be some delays in the approval process.
For more insights on microbiome-targeting therapeutics in immunology, download a free report sample
Report 4: Thematic Research: Gene Therapy in Oncology
There are currently just 3 gene therapies marketed for oncology indications in the eight major pharmaceutical markets (8 MM) (the US, France, Germany, Italy, Spain, the UK, Japan, and China). The market for gene therapies, especially those using viral vectors, is expected to be slowed down by the high cost of therapies, which may limit their accessibility. There are currently three marketed gene therapies for cancer indications and 81 in vivo gene therapies in development across the 8MM. Viral vector gene therapies have a high list price when they come to market. This restricts patient access, especially in countries where the healthcare systems are less developed.
For more insights on gene therapy in oncology, download a free report sample
#NA
Thematic Research: Neuroimmunology Drug Development
Thematic Research: Microbiome-Targeting Therapeutics in Immunology
Thematic Research: Gene Therapy in Oncology
Table of Contents
Frequently asked questions
-
The State of the Biopharmaceutical Industry 2022
-
What will remain an integral part of the future of pharmaceutical research and healthcare service delivery?
AI, followed by big data, will continue to trend as an integral part of the future of pharmaceutical research and healthcare service delivery.
-
Thematic Research: Neuroimmunology Drug Development
-
What was the market size of the top 20 neuroimmunology products by sales across the 8MM in 2020?
The market size of the top 20 neuroimmunology products by sales across the 8MM was $20.1 billion in 2020.
-
Thematic Research: Microbiome-Targeting Therapeutics in Immunology
-
What type of biotech companies currently dominate the pipeline for microbiome-targeting therapeutics?
Small and mid-sized biotech companies currently dominate the pipeline for microbiome-targeting therapeutics.
-
Thematic Research: Gene Therapy in Oncology
-
How many marketed gene therapies for cancer indications are there currently across the 8MM?
Currently, there are three marketed gene therapies for cancer indications across the 8MM (the US, France, Germany, Italy, Spain, the UK, Japan, and China).
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.